- Home
- URGN vs LX Comparison
URGN vs LX Comparison
Compare URGN & LX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- URGN
- LX
- Stock Information
- Founded
- URGN 2004
- LX 2013
- Country
- URGN United States
- LX China
- Employees
- URGN N/A
- LX N/A
- Industry
- URGN Biotechnology: Pharmaceutical Preparations
- LX Finance: Consumer Services
- Sector
- URGN Health Care
- LX Finance
- Exchange
- URGN Nasdaq
- LX Nasdaq
- Market Cap
- URGN 904.0M
- LX 1.1B
- IPO Year
- URGN 2017
- LX 2017
- Fundamental
- Price
- URGN $18.79
- LX $5.71
- Analyst Decision
- URGN Strong Buy
- LX
- Analyst Count
- URGN 8
- LX 0
- Target Price
- URGN $28.50
- LX N/A
- AVG Volume (30 Days)
- URGN 1.1M
- LX 3.1M
- Earning Date
- URGN 11-05-2025
- LX 08-07-2025
- Dividend Yield
- URGN N/A
- LX 6.79%
- EPS Growth
- URGN N/A
- LX 86.38
- EPS
- URGN N/A
- LX 1.28
- Revenue
- URGN $94,238,000.00
- LX $1,956,013,429.00
- Revenue This Year
- URGN $39.63
- LX $5.90
- Revenue Next Year
- URGN $111.49
- LX $21.30
- P/E Ratio
- URGN N/A
- LX $4.46
- Revenue Growth
- URGN 10.85
- LX 0.80
- 52 Week Low
- URGN $3.42
- LX $1.63
- 52 Week High
- URGN $21.71
- LX $11.64
- Technical
- Relative Strength Index (RSI)
- URGN 48.50
- LX 35.34
- Support Level
- URGN $18.45
- LX $5.83
- Resistance Level
- URGN $21.71
- LX $6.23
- Average True Range (ATR)
- URGN 1.18
- LX 0.22
- MACD
- URGN -0.18
- LX -0.04
- Stochastic Oscillator
- URGN 17.51
- LX 5.44
About URGN UroGen Pharma Ltd.
UroGen Pharma Ltd is a clinical-stage biotechnology firm specializing in solutions for urothelial and specialty cancers. The company has developed RTGel reverse-thermal hydrogel, a proprietary technology enhancing the therapeutic profiles of existing drugs by enabling sustained release. Their flagship product, Jelmyto (mitomycin) for pyelocalyceal solution, along with investigational candidate UGN-102 (mitomycin) for intravesical solution, targets non-surgical tumor ablation in forms of non-muscle invasive urothelial cancer. Additionally, their immuno-uro-oncology pipeline includes UGN-301 (zalifrelimab), an anti-CTLA-4 antibody, intended for both monotherapy and combination therapy. Revenue is generated from product sales.
About LX LexinFintech Holdings Ltd.
LexinFintech Holdings Ltd is an online consumer finance platform and a technology-driven service provider in China. The group is engaged in online direct sales services and online consumer finance services for its customers in the PRC. Geographically, it derives revenue from China.